Table of contents

Original articles

• Pathology detection rate of spectral domain optical coherence tomography devices (25 February, 2014)

  Sumit Sharma, Kaori Sayanagi, Peter K Kaiser
• What is the evidence for systemic effects of intravitreal anti-VEGF agents, and should we be concerned? (10 December, 2013)

  Robert L Avery
• Safety profiles of anti-VEGF drugs: bevacizumab, ranibizumab, aflibercept and ziv-aflibercept on human retinal pigment epithelium cells in culture (17 May, 2014)

  Deepika Malik, Mohamed Tarek, Javier Caceres del Carpio, Claudio Ramirez, David Boyer, M Cristina Kenney, Baruch D Kuppermann
• Early initial clinical experience with intravitreal aflibercept for wet age-related macular degeneration (2 May, 2014)

  Philip J Ferrone, Farihah Anwar, Jonathan Naysan, Khurram Chaudhary, David Fastenberg, Kenneth Graham, Vincent Deramo
• A single-arm, investigator-initiated study of the efficacy, safety and tolerability of intravitreal aflibercept injection in subjects with exudative age-related macular degeneration, previously treated with ranibizumab or bevacizumab: 6-month interim analysis (17 May, 2014)

  Rishi P Singh, Sunil Srivastava, Justis P Ehlers, Rumneek Bedi, Andrew P Schachat, Peter K Kaiser